Rhythm Pharmaceuticals (RYTM) Payables (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Payables for 11 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 3.25% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (up 3.25% YoY), while the FY2025 annual figure was $13.9 million, up 13.13% from the prior year.
• Payables retreated to $12.3 million in Q1 2026 per RYTM's latest filing, from $13.9 million in the prior quarter.
• Across five years, Payables topped out at $16.0 million in Q2 2025 and bottomed at $3.8 million in Q3 2023.
• Historically, Payables has averaged $9.1 million across 5 years, with a median of $8.4 million in 2023.
• Annual changes were most pronounced in 2024 — Payables sank 45.81% — and 2025, when it surged 251.79%.
• Rhythm Pharmaceuticals' Payables stood at $4.8 million in 2022, then gained by 1.83% to $4.9 million in 2023, then surged by 152.36% to $12.3 million in 2024, then advanced by 13.13% to $13.9 million in 2025, then decreased by 11.82% to $12.3 million in 2026.
• Business Quant data shows RYTM's Payables at $12.3 million in Q1 2026, $13.9 million in Q4 2025, and $13.6 million in Q3 2025.